[go: up one dir, main page]

US20100048603A1 - Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives - Google Patents

Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives Download PDF

Info

Publication number
US20100048603A1
US20100048603A1 US12/526,225 US52622508A US2010048603A1 US 20100048603 A1 US20100048603 A1 US 20100048603A1 US 52622508 A US52622508 A US 52622508A US 2010048603 A1 US2010048603 A1 US 2010048603A1
Authority
US
United States
Prior art keywords
carcinoma
tumor
formula
head
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/526,225
Other versions
US8853233B2 (en
Inventor
Claudio Pisano
Loredana Vesci
Franco Zunino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale per lo Studio e la Cura die Tumori
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Assigned to ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI, SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. reassignment ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PISANO, CLAUDIO, VESCI, LOREDANA, ZUNINO, FRANCO
Publication of US20100048603A1 publication Critical patent/US20100048603A1/en
Application granted granted Critical
Publication of US8853233B2 publication Critical patent/US8853233B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the use of a subclass of camptothecin derivatives for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, for example squamous oral, epidermoid submaxillary salivary gland or squamous pharynx carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma, epidermoid skin carcinoma.
  • a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, for example squamous oral, epidermoid submaxillary salivary gland or squamous pharynx carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma, epidermoid skin carcinoma.
  • Camptothecin derivatives are DNA-topoisomerase I inhibitors that have emerged as a prominent class of anticancer agents. Together with the taxanes, the topoisomerase I inhibitors are presumably the most important new class of anticancer drugs introduced into clinical practice.
  • Pre-clinical studies demonstrated significant in vitro and in vivo activity of topoisomerase I inhibitors, such as camptothecin and its derivatives, on a broad range of tumors. The results from clinical trials were promising, as shown by the registration of two topoisomerase inhibitors, topotecan and irinotecan (also known as CPT-11), in many European countries and in the USA, for treatment of patients with ovarian and colorectal cancer, respectively.
  • Other derivatives are currently at different stages of clinical development.
  • camptothecin derivatives which bear an alkyloxime O-substituted at position 7 and which are endowed with antitumor activity higher than the compound of reference topotecan. Moreover these camptothecin derivatives bearing an imino group on position 7, also show an improved therapeutic index. Among these compounds one of the preferred molecules was shown to be 7-t-butoxyiminomethylcamptothecin (CPT 184, also known as ST1481 orgimatecan).
  • camptothecin derivatives have shown a superior efficacy with respect to the reference compound (irinotecan) in terms of tumor volume inhibition (TVI %), log cell kill (LCK), which is a measure of reduction of the tumor size, complete response (CR) or long term survivors (LTS) against a wide spectrum of tumor xenografts in vivo.
  • TVI tumor volume inhibition
  • LCK log cell kill
  • CR complete response
  • LTS long term survivors
  • R is hydrogen or C 1 -C 4 alkyl, for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, for example squamous oral, epidermoid submaxillary salivary gland or squamous pharynx carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.
  • a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, for example squamous oral, epidermoid submaxillary salivary gland or squamous pharynx carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.
  • Compounds of Formula (I) also comprise tautomers, geometrical isomers, optically active forms as enantiomers, diastereomers and racemate forms, as well as pharmaceutically acceptable salts of the compounds of Formula (I).
  • Preferred pharmaceutically acceptable salts of the Formula (I) are acid addition salts formed with pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, and para-toluenesulfonate salts.
  • pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, and para-toluenesulfonate salts.
  • R is hydrogen or methyl.
  • Preferred compounds of Formula (I) are:
  • the compounds of Formula (I) may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used, unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimisation procedures. Specific reference is made to the methods described in patent application EP1044977 and in J. Med. Chem. 2001, 44, 3264-3274.
  • a method of treating a mammal suffering from a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, for example squamous oral, epidermoid submaxillary salivary gland or squamous pharynx carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma, epidermoid skin carcinoma, comprising administering a therapeutically effective amount of a compound of Formula (I) as described above represents one of the aspects of the present invention.
  • terapéuticaally effective amount refers to an amount of a therapeutic agent needed to treat, ameliorate a targeted disease or condition, or to exhibit a detectable therapeutic effect.
  • the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice or rats.
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • an effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination (s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 100 mg/kg, preferably 0.05 mg/kg to 50 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.
  • the medicament may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent.
  • a pharmaceutically acceptable carrier for administration of a therapeutic agent.
  • Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.
  • Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.
  • Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
  • compositions of the invention can be administered directly to the subject.
  • the subjects to be treated can be animals; in particular, human subjects can be treated.
  • the medicament of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra- arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal, rectal means or locally on the diseased tissue after surgical operation.
  • routes including, but not limited to, oral, intravenous, intramuscular, intra- arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal, rectal means or locally on the diseased tissue after surgical operation.
  • Dosage treatment may be a single dose schedule or a multiple dose schedule.
  • ST1968 delivered intravenously showed a wide spectrum of efficacy against different xenograft tumor models.
  • ST1968 was compared to irinotecan or other known chemotherapeutic agents against head and neck carcinoma (KB squamous oral, A253 epidermoid submaxillary salivary gland, FaDu squamous pharynx), MiaPaCa2 pancreas ca., 501Mel melanoma, HT1376 bladder ca., MESO mesothelioma, A431 epidermoid skin ca.
  • Exponentially growing tumor cells were injected s.c. into nude athymic mice. The number of tumor cells was previously chosen by a growth curve. Mice were housed inside cages of makrolon (33.2 ⁇ 15 ⁇ 13 cm) with stainless steel cover-feed and sterilized and dust-free bedding cobs. Animals were housed under a light-dark cycle, keeping temperature and humidity constant. Parameters of the animal rooms were assessed as follows: 22 ⁇ 2° C. temperature, 55 ⁇ 10% relative humidity, about 15-20 filtered air changes/hour and 12 hour circadian cycle of artificial light (7 a.m., 7 p.m.). At request, the environmental conditions were monitored and the data are retained in Animal Housing Archives. Drinking water was supplied ad libitum.
  • Each mouse was offered daily a complete pellet diet (GLP 4RF21, Mucedola) throughout the study.
  • the analytical certificates of animal food and water are retained at Sigma-Tau premises. All animals were weighed before starting the experiment and were subdivided into the different dosage groups.
  • Each cage was identified by a paper tag indicating: cage number, group, date of tumor injection, starting date of treatment, name of the test item, dose and route of administration, date of sacrifice.
  • Tumor growth was followed by biweekly measurements of tumor diameters with a Vernier caliper.
  • Tumor volume (TV, mm 3 ) was calculated as: [length (mm) ⁇ width (mm) 2 ]/2, where the width and the length are the shortest and the longest diameters of each tumor, respectively.
  • T and C are the mean times (days) required for treated (T) and control (C) tumor, respectively, to reach 1000 mm 3
  • DT is the doubling time of control tumors
  • CR meaning no evidence of tumor lasting for at least 10 days.
  • LTS long term survivors
  • Therapeutic index was evaluated as ratio between MTD (maximum tolerate dose) and ED80 (efficacious dose) of ST1968.
  • ST1968 revealed a potent antitumor effect against head and neck (KB, A253, FaDu) and epidermoid skin (A431) tumor xenograft models since it was able to induce a high number of long term survivors (LTS).
  • ST1968 showed to be more efficacious in terms of tumor volume inhibition (TVI %), log cell kill (LCK), complete response (CR) or long term survivors (LTS) against different tumor xenografts (KB, A253, MiaPaca2, lo HT1376, MeSO, A431).
  • ST1968 was more potent for its major persistence of effect on tumor growth upon the end of the treatment (see LCK and LTS). Moreover the therapeutic index of ST1968 evaluated on A253 tumor model was higher than that found with irinotecan (2.0 vs 1.0, respectively), suggesting a major tolerability apart from the high antitumor effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.

Description

    FIELD OF THE INVENTION
  • The present invention relates to the use of a subclass of camptothecin derivatives for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, for example squamous oral, epidermoid submaxillary salivary gland or squamous pharynx carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma, epidermoid skin carcinoma.
    • BACKGROUND OF THE INVENTION
  • Camptothecin derivatives are DNA-topoisomerase I inhibitors that have emerged as a prominent class of anticancer agents. Together with the taxanes, the topoisomerase I inhibitors are presumably the most important new class of anticancer drugs introduced into clinical practice. Pre-clinical studies demonstrated significant in vitro and in vivo activity of topoisomerase I inhibitors, such as camptothecin and its derivatives, on a broad range of tumors. The results from clinical trials were promising, as shown by the registration of two topoisomerase inhibitors, topotecan and irinotecan (also known as CPT-11), in many European countries and in the USA, for treatment of patients with ovarian and colorectal cancer, respectively. Other derivatives are currently at different stages of clinical development.
  • In patent application EP1044977 and in J. Med. Chem. 2001, 44, 3264-3274, camptothecin derivatives are described which bear an alkyloxime O-substituted at position 7 and which are endowed with antitumor activity higher than the compound of reference topotecan. Moreover these camptothecin derivatives bearing an imino group on position 7, also show an improved therapeutic index. Among these compounds one of the preferred molecules was shown to be 7-t-butoxyiminomethylcamptothecin (CPT 184, also known as ST1481 orgimatecan).
  • One of the main limitations of tumor therapies available today is the resistance of some kind of tumors to chemotherapy treatment (including camptothecin treatment). Moreover, despite of preliminary promising results, it is very difficult to find a drug, which is able to treat successfully different kinds of tumors.
    • DESCRIPTION OF THE INVENTION
  • It has now surprisingly found that two camptothecin derivatives have shown a superior efficacy with respect to the reference compound (irinotecan) in terms of tumor volume inhibition (TVI %), log cell kill (LCK), which is a measure of reduction of the tumor size, complete response (CR) or long term survivors (LTS) against a wide spectrum of tumor xenografts in vivo.
  • Moreover the therapeutic index of these two camptothecin derivatives evaluated in some animal models was higher than that found with irinotecan (2.0 vs 1.0, respectively), suggesting a major tolerability in addition to the high antitumor effect.
  • In particular the main object of the present invention is the use of a compound of Formula I,
  • Figure US20100048603A1-20100225-C00001
  • where R is hydrogen or C1-C4 alkyl, for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, for example squamous oral, epidermoid submaxillary salivary gland or squamous pharynx carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.
  • Compounds of Formula (I) also comprise tautomers, geometrical isomers, optically active forms as enantiomers, diastereomers and racemate forms, as well as pharmaceutically acceptable salts of the compounds of Formula (I).
  • Preferred pharmaceutically acceptable salts of the Formula (I) are acid addition salts formed with pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, and para-toluenesulfonate salts.
  • Preferably R is hydrogen or methyl.
  • Preferred compounds of Formula (I) are:
    • 7-(2-amino)ethoxyiminomethylcamptothecin, (ST1968, also known as CPT188) and 7-(2-dimethylamino)ethoxyiminomethylcamptothecin (ST1969).
  • The compounds of Formula (I) may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used, unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimisation procedures. Specific reference is made to the methods described in patent application EP1044977 and in J. Med. Chem. 2001, 44, 3264-3274.
  • A method of treating a mammal suffering from a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, for example squamous oral, epidermoid submaxillary salivary gland or squamous pharynx carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma, epidermoid skin carcinoma, comprising administering a therapeutically effective amount of a compound of Formula (I) as described above represents one of the aspects of the present invention.
  • The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate a targeted disease or condition, or to exhibit a detectable therapeutic effect.
  • For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice or rats.
  • The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination (s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 100 mg/kg, preferably 0.05 mg/kg to 50 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.
  • The medicament may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.
  • Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.
  • A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).
  • Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
  • Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.
  • The medicament of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra- arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal, rectal means or locally on the diseased tissue after surgical operation.
  • Dosage treatment may be a single dose schedule or a multiple dose schedule.
  • The invention will now be illustrated in greater detail by means of non-limiting Examples.
    • EXAMPLES IN VIVO ANTITUMORAL ACTIVITY ON DIFFERENT TUMOR XENOGRAFT MODELS
  • ST1968 delivered intravenously showed a wide spectrum of efficacy against different xenograft tumor models. Using a q4dx4 schedule, ST1968 was compared to irinotecan or other known chemotherapeutic agents against head and neck carcinoma (KB squamous oral, A253 epidermoid submaxillary salivary gland, FaDu squamous pharynx), MiaPaCa2 pancreas ca., 501Mel melanoma, HT1376 bladder ca., MESO mesothelioma, A431 epidermoid skin ca.
    • Methods
  • Exponentially growing tumor cells were injected s.c. into nude athymic mice. The number of tumor cells was previously chosen by a growth curve. Mice were housed inside cages of makrolon (33.2×15×13 cm) with stainless steel cover-feed and sterilized and dust-free bedding cobs. Animals were housed under a light-dark cycle, keeping temperature and humidity constant. Parameters of the animal rooms were assessed as follows: 22±2° C. temperature, 55±10% relative humidity, about 15-20 filtered air changes/hour and 12 hour circadian cycle of artificial light (7 a.m., 7 p.m.). At request, the environmental conditions were monitored and the data are retained in Animal Housing Archives. Drinking water was supplied ad libitum. Each mouse was offered daily a complete pellet diet (GLP 4RF21, Mucedola) throughout the study. The analytical certificates of animal food and water are retained at Sigma-Tau premises. All animals were weighed before starting the experiment and were subdivided into the different dosage groups. Each cage was identified by a paper tag indicating: cage number, group, date of tumor injection, starting date of treatment, name of the test item, dose and route of administration, date of sacrifice.
  • Tumor growth was followed by biweekly measurements of tumor diameters with a Vernier caliper. Tumor volume (TV, mm3) was calculated as: [length (mm)×width (mm)2]/2, where the width and the length are the shortest and the longest diameters of each tumor, respectively.
  • The efficacy of the drug treatment was assessed as: a) Tumor volume inhibition (TVI %) in treated versus control mice, calculated as: 100−[(mean tumor volume of treated animals/mean tumor volume of control animals)×100]; b) LCK (log10 cell kill) calculated by the formula LCK=(T−C)/3.32×DT, where T and C are the mean times (days) required for treated (T) and control (C) tumor, respectively, to reach 1000 mm3, and DT is the doubling time of control tumors; CR meaning no evidence of tumor lasting for at least 10 days. LTS (long term survivors) were considered mice without tumor 90 days upon the tumor injection.
  • The toxicity of the drug treatments was determined as: body weight loss percent (% BWL max)=100−(mean BWday x/mean BWday 1×100), where BWx is the mean BW at the day of maximal loss during the treatment and BW1 is the mean BW on the 1st day of treatment.
  • Therapeutic index was evaluated as ratio between MTD (maximum tolerate dose) and ED80 (efficacious dose) of ST1968.
    • Results
  • ST1968 revealed a potent antitumor effect against head and neck (KB, A253, FaDu) and epidermoid skin (A431) tumor xenograft models since it was able to induce a high number of long term survivors (LTS). Compared with the reference compound irinotecan, ST1968 showed to be more efficacious in terms of tumor volume inhibition (TVI %), log cell kill (LCK), complete response (CR) or long term survivors (LTS) against different tumor xenografts (KB, A253, MiaPaca2, lo HT1376, MeSO, A431). Compared with cisplatin in pharynx tumor bearing mice, ST1968 was more potent for its major persistence of effect on tumor growth upon the end of the treatment (see LCK and LTS). Moreover the therapeutic index of ST1968 evaluated on A253 tumor model was higher than that found with irinotecan (2.0 vs 1.0, respectively), suggesting a major tolerability apart from the high antitumor effect.
  • TABLE 1
    DOSE
    (mg/kg) RESULTS
    TUMOR XENOGRAFT COMPOUND AND ROUTE SCHEDULE TVI % LCK CR LTS
    Squamous oral ST1968 35 i.v. q4 d × 4 100 >>4.0 7/7 7/7
    KB
    17.5 i.v.   q4 d × 4 99 3.79 4/8 4/8
    irinotecan 60 i.v. q4 d × 4 92 1.63 0/8 0/8
    30 i.v. q4 d × 4 74 1.26 0/7 0/7
    Epidermoid ST1968 35 i.v. q4 d × 4 96 1.5 0/7 2/7
    submaxillary salivary
    gland
    A253
    30 i.v. q4 d × 4 90 1.2 0/8 1/8
    15 i.v. q4 d × 4 84 0.6 0/8 0/8
    irinotecan 60 i.v. q4 d × 4 79 0.5 0/8 0/8
    30 i.v. q4 d × 4 33 0.1 0/8 0/8
    Squamous pharynx ST1968 35 i.v. q4 d × 4 100 >>3.9 7/7 7/7
    FaDu
    30 i.v. q4 d × 4 100 >>3.9 8/8 8/8
    15 i.v. q4 d × 4 100 >>3.9 8/8 8/8
    irinotecan 60 i.v. q4 d × 4 100 >>3.9 8/8 8/8
    30 i.v. q4 d × 4 100 >>3.9 8/8 8/8
    cisplatin  7 i.v. q7 d × 3 99 3.9 1/8 3/8
    4.7 i.v.  q7 d × 3 93 1.6 1/8 0/8
    Pancreas ST1968 30 i.v. q4 d × 4 89 1.67 0/8 0/8
    MiaPaCa2
    17.5 i.v.   q4 d × 4 75 1.23 0/7 0/7
    irinotecan 60 i.v. q4 d × 4 69 1.23 0/7 0/7
    Melanoma ST1968 30 i.v. q4 d × 4 68 1.4  0/10  0/10
    501Mel
    20 i.v. q4 d × 4 65 1.0 0/6 0/6
    irinotecan 50 i.v. q4 d × 4 70 1.3  0/10  0/10
    Bladder ST1968 30 i.v. q4 d × 4 77 0.5  1/12  0/12
    HT1376
    irinotecan 50 i.v. q4 d × 4 46 0.2  0/10  0/10
    Mesothelioma ST1968 30 i.v. q4 d × 4 92 1.4  2/12  0/12
    MESO
    irinotecan 50 i.v. q4 d × 4 76 0.8  0/12  0/12
    Epidermoid skin ST1968 30 i.v. q4 d × 4 100 >>7.7 12/12 12/12
    A431
    irinotecan 50 i.v. q4 d × 4 100 6.8 12/12  9/12
    Therapeutic Index as MTD/ED80 on A253: 2.0 for ST1968, 1.0 for irinotecan.

    When the number in the column of LCK was defined as >>, it was not possible to calculate a LCK value 90 days after tumor injection because the tumor lesion was completely absent or present only in some of treated mice.

Claims (8)

1. (canceled)
2. The method according to claim 5, wherein R is hydrogen or methyl.
3. The method according to claim 5, wherein the head and neck carcinoma is selected from the group comprising squamous oral, epidermoid submaxillary salivary gland and squamous pharynx carcinoma.
4. A process for preparing a pharmaceutical composition for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidennoid skin carcinoma, comprising mixing a compound of Formula I,
Figure US20100048603A1-20100225-C00002
where R is hydrogen or C1-C4 alkyl, with pharmaceutically acceptable carriers and/or excipients.
5. Method of treating a mammal suffering from a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidemioid skin carcinoma, comprising administering a therapeutically effective amount of a compound of Formula I,
Figure US20100048603A1-20100225-C00003
where R is hydrogen or C1-C4 alkyl, or a pharmaceutical composition containing pharmaceutically acceptable carriers and/or excipients.
6. The method of claim 5, wherein the compound of Formula I is
7-(2-amino)ethoxyiminomethylcamptotllecin or
7-(2-diiethylamino)ethoxyiminomethylcamptothecin.
7. The method of claim 5, wherein the therapeutically effective amount is from 0.01 mg/kg to 100 mg/kg.
8. The method of claim 5, wherein the therapeutically effective amount is from 0.05 mg/kg to 50 mg/kg.
US12/526,225 2007-02-13 2008-02-07 Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives Expired - Fee Related US8853233B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07102209 2007-02-13
EP07102209 2007-02-13
EP07102209.9 2007-02-13
PCT/EP2008/000928 WO2008098701A1 (en) 2007-02-13 2008-02-07 Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives

Publications (2)

Publication Number Publication Date
US20100048603A1 true US20100048603A1 (en) 2010-02-25
US8853233B2 US8853233B2 (en) 2014-10-07

Family

ID=38283046

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/526,225 Expired - Fee Related US8853233B2 (en) 2007-02-13 2008-02-07 Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives

Country Status (3)

Country Link
US (1) US8853233B2 (en)
EP (1) EP2120948A1 (en)
WO (1) WO2008098701A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180244111A1 (en) * 2015-09-04 2018-08-30 Fang Zhu Truck tire tread and truck tire

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784277A (en) 2007-08-01 2010-07-21 希格马托制药工业公司 Treatment of pediatric tumors
ES3013327T3 (en) 2021-08-16 2025-04-11 General Electric Renovables Espana Sl A system comprising a structure being prone to lightning strikes and icing, a method for operating the system and a wind turbine comprising the system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242457B1 (en) * 1999-03-09 2001-06-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
US20080033003A1 (en) * 2004-05-13 2008-02-07 Claudio Pisano Camptothecins Conjugated in Position 7 to Cyclic Peptides as Cytostatic Agents
US7888368B2 (en) * 2005-12-21 2011-02-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of drug-resistant tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022041A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Mutations and polymorphisms of hdac3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242457B1 (en) * 1999-03-09 2001-06-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
US20080033003A1 (en) * 2004-05-13 2008-02-07 Claudio Pisano Camptothecins Conjugated in Position 7 to Cyclic Peptides as Cytostatic Agents
US7888368B2 (en) * 2005-12-21 2011-02-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of drug-resistant tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dallavalle et al. J. Med. Chem., 2001, vol. 44, pages 3264-3274 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180244111A1 (en) * 2015-09-04 2018-08-30 Fang Zhu Truck tire tread and truck tire

Also Published As

Publication number Publication date
US8853233B2 (en) 2014-10-07
WO2008098701A1 (en) 2008-08-21
EP2120948A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
US11464767B2 (en) Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
KR20060073538A (en) Abuse Prevention Amphetamine Compounds
CA2869557A1 (en) Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
TW200940062A (en) Combination comprising paclitaxel for treating ovarian cancer
US8853233B2 (en) Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
US8829021B2 (en) Treatment of pediatric tumors
EP2153821A1 (en) Oral formulations of camptothecin derivatives
CA2633112A1 (en) A method of treating tumors with azaxanthones
US7863255B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
CA2631868C (en) Treatment of drug-resistant tumors
WO2012167243A1 (en) Compositions and methods of treatment for obesity
MX2008015399A (en) Drug administration methods.
AU2008282024B2 (en) Treatment of pediatric tumors
WO2024129875A1 (en) Combination therapies for treating cancer
HK1142810A (en) Treatment of pediatric tumors

Legal Events

Date Code Title Description
AS Assignment

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.,I

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PISANO, CLAUDIO;VESCI, LOREDANA;ZUNINO, FRANCO;REEL/FRAME:023255/0525

Effective date: 20090908

Owner name: ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PISANO, CLAUDIO;VESCI, LOREDANA;ZUNINO, FRANCO;REEL/FRAME:023255/0525

Effective date: 20090908

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PISANO, CLAUDIO;VESCI, LOREDANA;ZUNINO, FRANCO;REEL/FRAME:023255/0525

Effective date: 20090908

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Expired due to failure to pay maintenance fee

Effective date: 20181007